UK markets open in 2 hours 59 minutes

Mayne Pharma Group Limited (HG6.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
4.2800+0.2600 (+6.47%)
At close: 08:01AM CEST
Currency in EUR

Valuation measures4

Market cap (intra-day) 350.32M
Enterprise value 279.03M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.04
Price/book (mrq)1.04
Enterprise value/revenue 1.04
Enterprise value/EBITDA -3.36

Trading information

Stock price history

Beta (5Y monthly) 1.32
52-week change 366.12%
S&P500 52-week change 325.01%
52-week high 34.3600
52-week low 31.6300
50-day moving average 33.9500
200-day moving average 33.0517

Share statistics

Avg vol (3-month) 312
Avg vol (10-day) 3N/A
Shares outstanding 585.07M
Implied shares outstanding 687.14M
Float 857.4M
% held by insiders 124.96%
% held by institutions 117.56%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 418 Jan 2023
Last split factor 21:20
Last split date 318 Jan 2023

Financial highlights

Currency in AUD.

Fiscal year

Fiscal year ends 30 Jun 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -76.21%
Operating margin (ttm)-20.19%

Management effectiveness

Return on assets (ttm)-5.46%
Return on equity (ttm)-40.74%

Income statement

Revenue (ttm)319.28M
Revenue per share (ttm)3.93
Quarterly revenue growth (yoy)259.80%
Gross profit (ttm)N/A
EBITDA -46.2M
Net income avi to common (ttm)-274.18M
Diluted EPS (ttm)-1.9200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)154.81M
Total cash per share (mrq)1.9
Total debt (mrq)36.58M
Total debt/equity (mrq)6.68%
Current ratio (mrq)1.61
Book value per share (mrq)6.74

Cash flow statement

Operating cash flow (ttm)-14.62M
Levered free cash flow (ttm)46.43M